Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

25%(1 trials)

Phase Distribution

Ph phase_2

50%

Ph phase_1

25%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

2(50.0%)

Phase 4Post-market surveillance

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (25.0%)

Phase 22 (50.0%)

Phase 41 (25.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

NCT02251041

completedphase_1

Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

NCT00945789

completedphase_4

The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction

NCT00882466

completedphase_2

The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)

NCT00336466

Clinical Trials (4)

Showing 4 of 4 trials

NCT02251041Phase 2

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Completed

NCT00945789Phase 1

Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)

Completed

NCT00882466Phase 4

The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction

Completed

NCT00336466Phase 2

The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS)

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4